Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

The NRG Oncology/Alliance clinical trial NRG-LU005, examining the addition of the immunotherapy drug atezolizumab combined with chemoradiation for patients with limited-stage small cell lung cancer (SCLC) recently reached the trial's accrual goal of 506 patients.

8 Jul 2022

Insight into the Breast Cancer Landscape with Breast Cancer Now

In this interview, we speak with Dr. Simon Vincent, Director of Research, Support, and Influencing at Breast Cancer Now, about the current landscape of breast cancer.

12 Apr 2022

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

11 Apr 2022

How malaria drugs could play a part in treating chemotherapy-resistant head and neck cancers

In this interview, we speak to Kirill Kiselyov, Ph.D, and Umamaheswar Duvvuri, M.D, Ph.D, from the University of Pittsburgh, about their latest research into hydroxychloroquine, a drug widely used to prevent and treat malaria, as a potential treatment for head and neck cancers.

28 Mar 2022

30-year-old cancer drug could get another shot, study says

A study by Virginia Commonwealth University Massey Cancer Center researchers published in today's print edition of Molecular Cancer Therapeutics shows that triplatin is effective against triple negative breast cancer, which is the most aggressive form of breast cancer and has few targeted therapies.

9 Feb 2022

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 overexpressing esophageal adenocarcinoma.

22 Jan 2022

A class of FDA-approved drugs can effectively stop aggressive uterine cancer

A team of scientists led by the University of Michigan Health Rogel Cancer Center has found that a class of U.S. Food and Drug Administration-approved drugs can effectively stop a highly aggressive type of uterine cancer in its tracks, paving a quick path toward new treatment strategies for a deadly cancer with limited therapeutic options.

17 Dec 2021

Study points to a new, effective treatment option for patients with mesothelioma

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

8 Nov 2021

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival in patients with nonsquamous non-small cell lung cancer with untreated and asymptomatic brain metastases.

12 Sep 2021

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

A combination of metformin and chemoradiation in patients with locally advanced non-small cell lung cancer (LA-NSCLC) was not found to add survival benefit in the NRG Oncology clinical trial NRG-LU001. These results were recently published in JAMA Oncology.

25 Aug 2021

Drug sensitivity of hepatocellular cancer cells may provide new insights on tumor biology

Oncotarget published "Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells" which reported that this study aimed to investigate whether Hepatocellular Cancer (HCC) cells cultured in more native conditions have an altered phenotype and drug sensitivity compared to those cultured in standard conditions.

8 Jun 2021

Carboplatin News and Research

Further Reading

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

Insight into the Breast Cancer Landscape with Breast Cancer Now

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

How malaria drugs could play a part in treating chemotherapy-resistant head and neck cancers

30-year-old cancer drug could get another shot, study says

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

A class of FDA-approved drugs can effectively stop aggressive uterine cancer

Study points to a new, effective treatment option for patients with mesothelioma

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

Drug sensitivity of hepatocellular cancer cells may provide new insights on tumor biology

Targeting mTOR pathway can improve the effectiveness of chemotherapies for pediatric brain cancer

Drug synthesized from Kentucky-grown plant shows promise in treating ovarian cancer

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

First-ever phase 3 advanced anal cancer trial opens for patient enrollment

New model can predict the risk of adverse side effects of cancer treatment

Combination therapy improves survival rates for women with aggressive endometrial cancer

International trial shows better option for treating people with inoperable anal cancer

Study finds carboplatin-paclitaxel as the optimal chemotherapy for anal cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News